History of GLP-1 Drugs: Complete Timeline From Exenatide (2005) to Tirzepatide and Beyond | PlexusDx
The complete history of GLP-1 drugs — from 1902 incretin research to exenatide (2005), Victoza (2010), Ozempic (2017), Rybelsus (2019), Wegovy (2021), Mounjaro (2022), Zepbound (2023), and pipeline candidates retatrutide and orforglipron — with where PlexusDx Semaglutide, Tirzepatide, Microdose, and GLP-Squared protocols fit in 2026.
GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.
Rybelsus (oral semaglutide) is FDA-approved for type 2 diabetes only — not for weight loss. See the real PIONEER weight numbers, the ~$998/month cash price, why insurance rarely covers off-label use, and how PlexusDx Semaglutide Oral ($209/mo+) and the Microdose GLP-1 Protocol ($129/mo) compare on cost and dose flexibility.
GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.
Retatrutide vs Orforglipron vs PlexusDx (2026): Pipeline GLP-1s, Real-World Options | PlexusDx
Retatrutide (Lilly's investigational triple agonist) and orforglipron (Lilly's oral non-peptide GLP-1) are the two big pipeline stories in 2026 — but neither is FDA-approved yet. Here's the realistic timeline, the Phase 3 data, the announced and unknown pricing, and how PlexusDx's currently-available compounded semaglutide and tirzepatide protocols ($129–$509/mo) compare for someone who needs an option today rather than in 2028.
GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.
Is oral tirzepatide FDA approved? No — only injectable Mounjaro and Zepbound are. Here's what compounded oral tirzepatide is, how PlexusDx Tirzepatide Oral ($229–$509/mo) fits, and the safety considerations that apply to both.
GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.